Organigram – Sanity Group Deal: What Changed and What it Means for Germany
This article was originally published in February 2026, and was most recently updated on September 22, 2026.
This article was originally published in February 2026, and was most recently updated on September 22, 2026.
Last week, we reported on an emerging trend in the European medical cannabis industry, which is seeing regulators in incoming markets favour alternative modes of administration, challenging the ubiquity of dried flower.
As Europe’s medical cannabis market shifts from a focus on growth to pharmaceutical discipline, PHCANN International has emerged as a leading voice in this new phase.
In the latest instalment of our series spotlighting the expert contributors to Prohibition Partners’ newly launched Insights Hub, we sat down with Enua to dicsuss the risks posed by Germany’s drift towards adult-use in its medical market, the company’s proposals for strengthening pharmacy-led distribution and introducing over-the-counter cannabis products, and its long-term mission to ensure…
Last month, Slovenia’s parliament passed a law to significantly open up access to medical cannabis, coinciding with the presentation of a separate draft law on legalisation for personal use.
Its unique position will set GROW apart from other players in the European market.